The FDA has cleared Teleflex to market its ARROW VPS G4 Device, which could be released in the U.S. during the second quarter of the year. The system is said to be the only such device designed to pinpoint the exact site of the lower 1/3 of the vena cava and cavo-atrial junction using micro-Doppler ultrasound combined with advanced algorithms and intravascular ECG.
Teleflex's vascular positioning device wins FDA nod
SmartBrief Job Listings for Health Care
|Director, Quality Assurance||
|Provider Relations Manager||
Breakthrough Behavioral, Inc.
|Redwood City, CA|
|Director Account Management||
Samaritan Health Services
|Hospital Medical Device Sales||
Linda Hertz Group